Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Intensifying Treatment in Childhood B-Lymphoblastic Leukemia with IKZF1 Deletions Negates Its Adverse Outcome: Results of Ma-Spore ALL 2003 and 2010 Studies

Yi Lu, PhD, Winnie Hui Ni Chin, Evelyn Huizi Lim, Shirley Kow Yin Kham, BSc, Ah Moy Tan, MD, Hany Ariffin, MD PhD, Allen Eng Juh Yeoh, MD

Blood (2017) 130 (Supplement 1): 478.

https://doi.org/10.1182/blood.V130.Suppl_1.478.478

Published: 2017

Journal Articles

Effective Response Metric (ERM-D8) Using Time-Series Gene Expression Profiling at Diagnosis and Day 8 of Remission-Induction Therapy Is a Novel Early Prognostic Marker to Predict Relapse in Childhood Acute Lymphoblastic Leukemia (ALL) — a Malaysia-Singapore ALL Study

Allen Eng Juh Yeoh, MD, Zhenhua Li, PhD, Difeng Dong, PhD, Yi Lu, PhD, Jan Trka, MD, PhD, Prof., Shirley Kow Yin Kham, B.Sc., Ah Moy Tan, MD, Hany Ariffin, MD, Limsoon Wong, PhD

Blood (2014) 124 (21): 2393.

https://doi.org/10.1182/blood.V124.21.2393.2393

Published: 2014

Journal Articles

Genomic Profiling of Pharmacogenetic Variants Establishes a SNP-Based Predictor for Poor Outcome in Asian Children with Acute Lymphoblastic Leukemia (ALL): A Report from Malaysia-Singapore ALL Study Group

Yi Lu, PhD, Marc Hai Liang Wong, M.B.,B.S., Zhenhua Li, PhD, Shirley Kow Yin Kham, B.Sc., Ah Moy Tan, MD, Hany Ariffin, MD, Allen Eng Juh Yeoh, MD

Blood (2014) 124 (21): 1069.

https://doi.org/10.1182/blood.V124.21.1069.1069

Published: 2014

Journal Articles

Single IGH/TCR MRD Marker Is More Informative and Cost-Effective in Risk-Stratified Therapy for Childhood ALL: Prospective Treatment Trial Results from the Malaysia-Singapore (Ma-Spore) ALL 2003 Study

Allen Eng Juh Yeoh, MD, Hany Ariffin, MD, Ah Moy Tan, MD, Thi Thu Ha Truong, BSc, Hai Peng Lin, MD, Yiong Huak Chan, PhD, Shirley Kow Yin Kham, BSc, Thuan Chong Quah, MD

Blood (2008) 112 (11): 2551.

https://doi.org/10.1182/blood.V112.11.2551.2551

Published: 2008

Journal Articles

Lymphoblasts Produce a Lysosomal Protease That Rapidly Degrades L-Asparaginase - Implications for Therapy in Childhood Acute Lymphoblastic Leukemia.

Naina Patel, BSc, Shekhar Krishnan, MD, Marc N. Offman, MSc, Cathy X. Moss, PhD, Hany Ariffin, MD, Fred W. vanDelft, MD, Olga Yiannikouris, PhD, Carly Leighton, BSc, Seema Alexander, MSc, Mark Holland, PhD, Doaa Khater, MD, Ji Zhong Liu, MD, PhD, Monika Essink, MD, Paul Bates, PhD, Colin Watts, FRS, Vaskar Saha, MD, PhD

Blood (2007) 110 (11): 2791.

https://doi.org/10.1182/blood.V110.11.2791.2791

Published: 2007

Journal Articles

MDR1 C3435T Polymorphism Is Highly Correlated with Early Response to Therapy and Outcome in Childhood Acute Lymphoblastic Leukaemia: Malaysia-Singapore 2003 ALL Study.

Shirley Kow Yin Kham, BSc, Hany Ariffin, MD, Yiong Huak Chan, PhD, Thuan Chong Quah, MD, Allen Eng Juh Yeoh, MD

Blood (2007) 110 (11): 226.

https://doi.org/10.1182/blood.V110.11.226.226

Published: 2007

Journal Articles

Genetic Polymorphisms in the Folate Pathway and Risk of Childhood Acute Lymphoblastic Leukemia (ALL): MTHFR, MTHFD1, RFC1 and TS.

Allen Eng-Juh Yeoh, MD, Shirley Kow-Yin Kham, BSc, Yi Lu, PhD, Toon-Chai Foo, BSc, Hany Ariffin, MD, Thuan-Chong Quah, MD

Blood (2006) 108 (11): 2274.

https://doi.org/10.1182/blood.V108.11.2274.2274

Published: 2006

NARROW

Intensifying Treatment in Childhood B-Lymphoblastic Leukemia with IKZF1 Deletions Negates Its Adverse Outcome: Results of Ma-Spore ALL 2003 and 2010 Studies

Effective Response Metric (ERM-D8) Using Time-Series Gene Expression Profiling at Diagnosis and Day 8 of Remission-Induction Therapy Is a Novel Early Prognostic Marker to Predict Relapse in Childhood Acute Lymphoblastic Leukemia (ALL) — a Malaysia-Singapore ALL Study

Genomic Profiling of Pharmacogenetic Variants Establishes a SNP-Based Predictor for Poor Outcome in Asian Children with Acute Lymphoblastic Leukemia (ALL): A Report from Malaysia-Singapore ALL Study Group

Single IGH/TCR MRD Marker Is More Informative and Cost-Effective in Risk-Stratified Therapy for Childhood ALL: Prospective Treatment Trial Results from the Malaysia-Singapore (Ma-Spore) ALL 2003 Study

Lymphoblasts Produce a Lysosomal Protease That Rapidly Degrades L-Asparaginase - Implications for Therapy in Childhood Acute Lymphoblastic Leukemia.

MDR1 C3435T Polymorphism Is Highly Correlated with Early Response to Therapy and Outcome in Childhood Acute Lymphoblastic Leukaemia: Malaysia-Singapore 2003 ALL Study.

Genetic Polymorphisms in the Folate Pathway and Risk of Childhood Acute Lymphoblastic Leukemia (ALL): MTHFR, MTHFD1, RFC1 and TS.

Email alerts

ASH Publications

American Society of Hematology

Intensifying Treatment in Childhood B-Lymphoblastic Leukemia with IKZF1 Deletions Negates Its Adverse Outcome: Results of Ma-Spore ALL 2003 and 2010 Studies

Effective Response Metric (ERM-D8) Using Time-Series Gene Expression Profiling at Diagnosis and Day 8 of Remission-Induction Therapy Is a Novel Early Prognostic Marker to Predict Relapse in Childhood Acute Lymphoblastic Leukemia (ALL) — a Malaysia-Singapore ALL Study

Genomic Profiling of Pharmacogenetic Variants Establishes a SNP-Based Predictor for Poor Outcome in Asian Children with Acute Lymphoblastic Leukemia (ALL): A Report from Malaysia-Singapore ALL Study Group

Single IGH/TCR MRD Marker Is More Informative and Cost-Effective in Risk-Stratified Therapy for Childhood ALL: Prospective Treatment Trial Results from the Malaysia-Singapore (Ma-Spore) ALL 2003 Study

Lymphoblasts Produce a Lysosomal Protease That Rapidly Degrades L-Asparaginase - Implications for Therapy in Childhood Acute Lymphoblastic Leukemia.

MDR1 C3435T Polymorphism Is Highly Correlated with Early Response to Therapy and Outcome in Childhood Acute Lymphoblastic Leukaemia: Malaysia-Singapore 2003 ALL Study.

Genetic Polymorphisms in the Folate Pathway and Risk of Childhood Acute Lymphoblastic Leukemia (ALL): MTHFR, MTHFD1, RFC1 and TS.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only